GlobeNewswire·Nov 5, 2026, 4:05 PM ET

MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares

MediWound Ltd. (Nasdaq: MDWD) announced the closing of a $17.25 million underwritten public offering of ordinary shares.
The offering consisted of 1,380,000 shares, including 180,000 shares issued upon full exercise of the underwriter's option.
Shares were sold at a public offering price of $12.50 per ordinary share.
H.C. Wainwright & Co. served as the sole book-running manager for the transaction.
Gross proceeds totaled $17.25 million before deducting underwriting discounts, commissions, & offering expenses.
MediWound intends to utilize net proceeds for working capital & general corporate purposes.
The offering was conducted pursuant to a shelf registration statement on Form F-3 filed with the SEC on March 19, 2025.
MediWound is a leader in enzymatic therapeutics for tissue repair, marketing the FDA-approved biologic NexoBrid® for thermal burns.
The company is developing EscharEx®, an investigational therapy for the debridement of chronic wounds.

Company: MediWound Ltd.
Keywords: Nasdaq:MDWD, MediWound Ltd., Announcement, financing, follow-on, funding